Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan

.

Source: Expert Opinion on Biological Therapy - October 21, 2022 Category: Drugs & Pharmacology Authors: Kentaro Harada Shun Yamamoto Ken Kato Source Type: research